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Background: Pathologic nodal stage is the key prognostic factor 
in resectable non–small-cell lung cancer (NSCLC). Mediastinal 
lymph node (MLN) metastasis connotes a poor prognosis. Yet, some 
NSCLC resections exclude MLN examination.
Methods: We analyzed U.S. Surveillance, Epidemiology, and End 
Results program data from 1998 to 2002 to quantify the long-term 
survival impact of failure to examine MLN in resected NSCLC. We 
used Kaplan–Meier methods to compare the unadjusted survival 
difference between patients with, and without, MLN examination, 
and Cox proportional hazards and competing risk models to serially 
adjust for the impact of risk factors on survival differences.
Results: Sixty-two percent of patients with pathologic N0 or N1 
NSCLC had no MLN examined. Overall 5-year survival rates were 
52% for those with, versus 47% for those without, MLN exami-
nation; lung cancer-specific survival rates were 63% versus 58% 
respectively (p < 0.001); nonlung cancer mortality was identical 
between cohorts. Adjusting for potential confounders, MLN exami-
nation was associated with a 7% reduction in all-cause mortality 
(hazard ratio, 0.93; confidence interval, 0.88–0.97; p = 0.002), and 
11% reduction in lung cancer-specific mortality (hazard ratio, 0.89; 
95% confidence interval, 0.84–0.95; p < 0.001) rates. The excess 
risk in 1 year’s cohort of U.S. lung resections was 3150 lives over 
5 years.
Conclusions: Failure to examine MLN was a common practice in 
MLN-negative NSCLC resections, which significantly impaired 
long-term survival. Efforts to understand the etiology of this quality 
gap, and measures to eliminate it, are warranted.
Key Words: Non–small-cell lung cancer, Surgical resection, 
Mediastinal lymph nodes, Quality of care, Outcome of care, Staging.
(J Thorac Oncol. 2012;7: 1798–1806)
Lung cancer kills 160,000 individuals annually in the United States1 and 1.4 million worldwide.2 Non–small-cell lung 
cancer (NSCLC) represents approximately 85% of all lung 
cancer cases in the United States. Most long-term survivors 
of NSCLC have had surgical resection for early-stage disease. 
Yet, patients who undergo surgical resection remain at high 
risk for death, with 5-year mortality rates ranging from 27% 
for stage IA, to 76% for stage IIIA disease.3
Lymph node (LN) status is the paramount determinant 
of long-term postoperative survival. The 5-year survival rates 
are 56% in pathologic (p) N0, 38% in pN1, 26% in pN2, and 
6% in pN3 disease.4 Identifying LN metastasis is important 
for accurate prognostication and selection of postoperative 
adjuvant therapy.5–8 Depending on the degree of thoroughness 
of application, preresection clinical staging underestimates 
pathologic stage in 10% to 40% of patients.9–11 Therefore 
clinically node-negative patients need pathologic staging. All 
LNs within the resected lung12 and certain mediastinal LNs 
(MLNs) should be examined.13
We hypothesized that failure to examine MLN leads 
to worse survival in patients who undergo resection for 
lung cancer, because of failure to identify MLN metastasis 
in a significant proportion, failure to accurately stratify risk, 
loss of putative benefits of surgical removal of LNs with 
metastasis, and (in recent times) failure to offer postoperative 
adjuvant therapy to high risk subsets. We examined the 
U.S. Surveillance, Epidemiology, and End Results database 
(SEER) to quantify the frequency and consequences of failure 
to examine MLN in patients with pN0 and pN1 disease 
(MLN-negative disease).
MATERIALS AND METHODS
With the approval of the University of Tennessee 
(Institutional Review Board no. 11-01649-XM), we queried 
the SEER lung cancer database in April 2012. SEER includes 
information on cancer incidence and survival from specific 
geographic areas, representing approximately 14% of the U.S. 
population during the time span included in our study.
Study Subjects
Study subjects had their first primary NSCLC diag-
nosed between 1998 and 2002 (because information on 
whether, or not, MLNs were examined is available in 
SEER only for resections performed during this period); 
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were 18 years or older; had received nonexploratory surgi-
cal resection to the primary site; had histologically con-
firmed diagnosis of NSCLC; and at least one LN examined 
after surgery. We excluded those with preoperative radia-
tion therapy, no examined LN (so-called pathologic NX) or 
unknown number of examined LNs, distant metastasis at 
the time of lung resection, and unknown surgical laterality 
(Fig. 1). We also excluded patients with MLN metastasis 
for all analyses except the estimation of the relative impact 
of MLN metastasis on survival of patients with and without 
MLN examination. Finally, we excluded patients who died 
within 30 days postoperatively from the long-term survival 
analyses.
Lymph Node Evaluation
Since 1988, SEER has routinely collected LN infor-
mation including the number examined, the number with 
metastasis, and the pN-category. However, the identification 
of anatomical locations from which LNs were collected dur-
ing surgery is only available between 1998 and 2002. This 
information is categorized as whether, or not, MLN were 
examined (yes or no). The number of MLN examined, num-
ber with metastasis, extent of MLN dissection, and informa-
tion about invasive preoperative MLN examination are not 
reported in SEER.
Patient Demographic and Clinical Characteristics
SEER includes demographic information such as age 
at cancer diagnosis, sex, race/ethnicity, and marital status. 
Available clinical information includes the year of diagno-
sis, tumor characteristics (size, grade, histology, and exten-
sion) and the first course, and timing, of radiation and surgery. 
Classification of histology was based on the third edition of 
the International Classification of Diseases for Oncology. 
SEER does not provide information about chemotherapy.
SURVIVAL
In 2012, the public release of SEER reported deaths 
up to December 31, 2009, including cause-specific mortality 
data obtained from death certificates. We determined overall 
survival from the date of diagnosis to the date of death 
(irrespective of cause) or end of follow-up, and cause-specific 
survival from date of diagnosis to date of death from the cause 
or end of follow-up.
Statistical Analysis
We compared demographic and clinical characteristics 
between those with and without MLN examination using the 
Pearson χ2 test for categorical variables, the t test for continu-
ous variables, trend test for ordered variables, log-rank test for 
mortality comparison, and the nonparametric rank-sum test for 
First primary NSCLC (SEER 1998 – 2002)
18 years or above, N=123,822
Had surgical resection, N= 23,865
No pre-operative radiotherapy, N = 22,460
At least 1 lymph node examined, N = 14,989
Stage I-III disease, N = 14,295
Final Study Cohort:
Resected NSCLC, no pre-operative radiation
therapy, at least 1 lymph node examined, stage
I-III with no MLN metastasis
N = 12,349  
No surgical resection, N=99,957
Unconfirmed histologic diagnosis, N=4
Pre-operative radiation, N=1016
Unknown laterality, N=168
Died within 30 days, N=217
No LNs examined, N=3,283
Unknown number of LNs, N=3,651
No surgical LN examined, N=537
Stage IV disease, N=598
Unknown stage, N=96
pN2 disease*, N=1,865
pN3 disease, N=81
EXCLUDED
FIGURE 1.  Cohort selection. *These patients 
were included in a specific analysis to estimate 
the impact of MLN metastasis on the popu-
lation without MLN examination. NSCLC, 
non–small-cell lung cancer; SEER, Surveillance, 
Epidemiology, and End Results database; 
MLN, mediastinal lymph nodes; LN, Lymph 
nodes.
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the number of LNs examined. We used Kaplan–Meier methods 
to visually compare the unadjusted survival difference between 
MLN examination cohorts. In the multivariate analysis, we 
used Cox proportional hazards model to examine overall sur-
vival, adjusted for the above-mentioned confounders. Because 
death by causes other than lung cancer was common among 
the lung cancer survivors, we used a competing risk model14 to 
examine the association between MLN examination and lung 
cancer–specific mortality. Death caused by lung cancer was 
the event of interest, death by other causes was the competing 
event, and those who survived were censored at December 31, 
2009. We also compared the non–lung-cancer deaths between 
MLN examination cohorts by treating the other causes of death 
as the outcome and death by lung cancer as the competing risk.
No variable selection procedure was attempted because 
all these confounders were chosen based on prior clinical 
knowledge and literature. We conducted sequential modeling 
in which these confounders were serially entered as groups. We 
also performed separated analyses for those with and without 
hilar/intrapulmonary (N1) LN metastasis. Different categori-
zation of variables and interaction analysis were explored. We 
conducted additional sensitivity analysis by restricting data to 
5-year survival, and also by excluding those who died within 
60 days, to account for possible differences in operative risk 
between those with and without MLN examination. Results 
from these models were similar to those reported (data not 
shown). Finally, we assessed the impact of MLN metastasis 
on survival by reintegrating patients with pN2 (who were 
excluded for all the preceding analyses and who, by definition, 
had received MLN examination) back into the data analysis.
We used Stata 12 (Stata Corp, College Station, TX) for 
all statistical analysis. All tests were two-sided, with a statisti-
cal significance level set at p values of 0.05 or lower. We also 
reported hazard ratios (HR) and 95% confidence intervals (CIs).
RESULTS
SEER included 12,349 patients who met our selection 
criteria (Fig. 1). The overall cohort characteristics are typi-
cal of a U.S. lung cancer surgical resection cohort (Table 1), 
with a median age of 66 years, a white predominance (86%), 
majority (69%) with stage I disease, and lobectomy as the 
TABLE 1.  Patient Demographic and Clinical Characteristics by Mediastinal Lymph Node Examination Status 
Characteristics
Overalla
n = 12,349
Mediastinal lymph nodes examinedb
p
Yes
n = 4638 (38%)
No
n = 7711 (62%)
Demographic factors
Age, years, mean (SD) 66.2 (10.3) 66.3 (10.3) 66.2 (10.3) 0.45
Age group, years
<50 793 (6) 299 (38) 494 (62) 0.86
50–64 4108 (33) 1522 (37) 2586 (63)
65–74 4630 (38) 1769 (38) 2861 (62)
≥75 2818 (23) 1048 (37) 1770 (62)
Race
White 10,557 (86) 4033 (38) 6524 (62) <0.001
Black 1033 (8) 324 (31) 709 (69)
Other 759 (6) 281 (37) 478 (63)
Sex
Male 6539 (53) 2371 (36) 4168 (64) 0.002
Female 5810 (47) 2267 (39) 3543 (61)
Marital status
Married 7364 (60) 2777 (38) 4587 (62) 0.67
Living alone 4985 (40) 1861 (37) 3124 (63)
Clinical factors
 Tumor location
Upper lobe 7320 (59) 2821 (39) 4499 (62) 0.012
Middle lobe 581 (5) 199 (34) 382 (66)
Lower lobe 3822 (31) 1372 (36) 2450 (64)
Multiple lobe or unspecified 626 (5) 246 (39) 380 (61)
Stage
I 8550 (69) 3245 (38) 5305 (62) <0.001
II 2168 (18) 734 (34) 1434 (66)
III 1631 (13) 659 (40) 972 (60)
(Continued)
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TABLE 1.  (Continued)
Characteristics
Overalla
n = 12,349
Mediastinal lymph nodes examinedb
p
Yes
n = 4638 (38%)
No
n = 7711 (62%)
Histology
Adenocarcinoma 5224 (42) 1946 (37) 3278 (63) 0.637
Squamous cell carcinoma 3648 (30) 1368 (38) 2280 (63)
Large-cell carcinoma 681 (6) 244 (36) 437 (64)
Bronchioalveolar cell carcinoma 1481 (12) 568 (38) 913 (62)
Other 1315 (11) 512 (39) 803 (61)
Tumor grade (differentiation)
Well 1273 (10) 454 (36) 819 (64) 0.001
Moderate 4535 (37) 1679 (37) 2856 (63)
Poor 4943 (40) 1938 (39) 3005 (61)
Undifferentiated 556 (5) 222 (40) 334 (61)
Other 1042 (8) 345 (33) 697 (67)
Tumor size (cm)
<3 5510 (45) 2065 (38) 3445 (63) 0.014
3–4.9 3972 (32) 1481 (37) 2491 (63)
≥5 2614 (21) 1019 (39) 1595 (61)
Unknown 253 (2) 73 (29) 180 (71)
Tumor extension
Confined to one lung 6885 (56) 2685 (39) 4200 (61) <0.001
Involving main stem bronchus 3833 (31) 1294 (34) 2539 (66)
Extended to pleura 1049 (9) 393 (38) 656 (63)
Extended to chest wall, carina, and farther 582 (5) 266 (46) 316 (54)
Treatment factors
Extent of resection
Lobectomy 9956 (81) 3663 (37) 6293 (63) 0.001
Pneumonectomy 1528 (12) 617 (40) 911 (60)
Other 865 (7) 358 (41) 507 (59)
Postsurgery radiation
No 10450 (85) 3953 (38) 6497 (62) 0.146
Yes 1899 (15) 685 (36) 1214 (64)
Number of LN examined, median (IQR) 6 (3–11) 9 (5–14) 5 (3–9) <0.001
LN metastasis detected
No (pN0) 9652 (78) 3717 (39) 5935 (62) <0.001
Yes (pN1) 2697 (22) 921 (34) 1776 (66)
Survival outcomes
Death in a year
No 10323 (84) 3947 (38) 6376 (62) <0.001
Yes 2026 (16) 691 (34) 1335 (66)
Overall death status
Alive 4268 (35) 1743 (41) 2525 (59) <0.001
Dead 8081 (65) 2895 (36) 5186 (64)
Cause specific death
Alive 4268 (35) 1743 (41) 2525 (59) <0.001
Lung cancer 5268 (43) 1838 (35) 3430 (65)
Other, not lung cancer 2813 (23) 1057 (38) 1756 (62)  
aShows counts and column percent.
bShows counts and row percent.
LN, lymph node; IQR, interquartile range; pN0, pathologic N0; pN1, pathologic N1.
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most common resection procedure (81%). Postoperative 
radiation therapy was administered to 15% of the patients. In 
4638 patients (38%), at least one MLN was examined; 7711 
patients (62%) had no MLN examined.
Factors Associated with MLN Examination
Women were slightly more likely than men to have 
MLNs examined, as were whites compared with African 
Americans. There was no association between other demo-
graphic factors and MLN examination (Table 1). Multiple 
tumor characteristics were associated with differences in 
MLN examination rate. It was highest in patients with upper 
lobe tumors, American Joint Committee on Cancer stage I dis-
ease, pN0 disease, poorly differentiated tumors, tumors larger 
than 5 cm, and tumors confined within the lung. There was no 
association with tumor histology. Pneumonectomy recipients 
were more likely to have MLN examination than those with a 
lesser resection. A higher total number of LNs was examined 
in those with MLN examination (median, 9; interquartile 
range, 5–14) than in those without (median, 5; interquartile 
range, 3–9; p < 0.001).
MLN Examination and Survival.
The 30-day mortality rate was similar: 0.64% for those 
with, versus 0.96% for those without, MLN examination (p = 
0.07). Survival was significantly associated with examination 
of MLN. Death within 1 year of surgery was more frequent 
in those without MLN examination (17%) than in those with 
examination (15%), p value less than 0.001. There were sig-
nificantly more deaths and deaths from lung cancer in those 
with no MLN (67% and 45%) than in those with MLN (62% 
and 40%), p value less than 0.001 (Table 1).
The unadjusted survival analysis shows that MLN 
examination was associated with better overall, and lung 
cancer-specific, survival (Fig. 2A and B). The overall 5-year 
survival rate was 49% for the whole cohort, 52% in the MLN 
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FIGURE 2. A, Overall survival curves of patients with and without examination of mediastinal lymph nodes after surgical resec-
tion for non–small-cell lung cancer: SEER database from 1998 to 2002. B, Lung cancer-specific survival curves of patients with 
and without examination of mediastinal lymph nodes after surgical resection for non–small-cell lung cancer: SEER database 
from 1998 to 2002. C, Survival curves for other causes of patients with and without examination of mediastinal lymph nodes 
after surgical resection for non–small-cell lung cancer: SEER database from 1998 to 2002. MLN, mediastinal lymph nodes; SEER, 
Surveillance, Epidemiology, and End Results database.
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examination cohort, compared with 47% in the group without 
examination (p < 0.001). The median overall survival was 5.3 
years in the group with, versus 4.4 years in the group without, 
MLN (p < 0.001). The 5-year lung-cancer–specific survival 
rate was 60% for the whole group, 63% in those with MLNs 
versus 58% in those without (p < 0.001). There was no differ-
ence in the non–lung-cancer specific survival rates between 
the MLN examination cohorts (Fig. 2C).
To adjust for the potential impact of risk factor hetero-
geneity, we compared the survival of patients in both cohorts 
using different risk-factor models by sequentially entering dif-
ferent groups of confounders (Table 2). With more confounders 
entering the models, the beneficial effect of MLN examination 
remained across all models, although it decreased from 11% 
to 7% for overall survival (all p < 0.05), and from 14% to 9% 
for lung-cancer–specific survival (all p < 0.05). This differ-
ence persisted even in an overadjusted model (model 4, Table 
2) that included both the number of LNs with metastasis and 
American Joint Committee on Cancer stage.
The separated analysis for those with and without N1 
LN metastasis yielded similar results. In patients with pN0, 
the benefit of MLN examination ranged from 7% improvement 
in overall survival in the least stringent model, to 5% in the 
most stringent. The improvement in lung-cancer–specific 
survival ranged from 8% to 7%. In those with pN1 disease, 
MLN examination improved overall survival by 18% to 12% in 
the various models. The improvement in lung-cancer–specific 
survival ranged from 21% to 14% (Table 2). In the model 
including patient demographics, clinical characteristics, and the 
number of LNs examined, MLN examination was associated 
with 7% lower all-cause mortality risk (HR, 0.93; 95%CI, 
0.88–0.97; p = 0.002) (Table 3). The lung-cancer–specific 
mortality risk reduction was 11% (HR, 0.89; 95% CI, 0.84–
0.95; p < 0.001). Furthermore, after incorporating patients 
with MLN metastasis back into the data, MLN examination 
was still associated with improved overall (HR, 0.94; 95%CI, 
0.90–0.98; p = 0.008), and lung-cancer–specific (HR, 0.94; 
95%CI, 0.89–0.99; p = 0.024), survival. The number of LNs 
examined (irrespective of location) was one of several other 
factors independently associated with survival (Table 3).
Assuming a 7% overall survival benefit of MLN exami-
nation, an annual case-volume of 45,000 lung resections for 
pN0 or pN1 NSCLC, and 22% of those with MLN examina-
tion having MLN metastasis, we estimate that failure to exam-
ine MLN is associated with an excess mortality risk, in 1 year’s 
cohort of U.S. lung resections, of 3150 lives over 5 years.
DISCUSSION
An oncologically sound lung cancer resection requires 
negative surgical margins and examination of sufficient hilar, 
intrapulmonary, and mediastinal LNs to accurately determine 
pathologic stage. MLNs must be provided by the surgeon, oth-
erwise the pathologist has no access to them. Most experts 
recommend a systematic nodal dissection that includes a 
minimum of three MLN stations.15–17 Prior studies have com-
pared the outcomes of patients who underwent surgical MLN 
staging of varying degrees of extensiveness.18–20 In this study, 
we quantified the incidence and survival impact of nonex-
amination of MLNs in a population-based series. Failure 
to examine MLNs was common and impactful. The greater 
impact on lung-cancer–specific survival, the greater effect 
size in patients with more advanced disease, and the absence 
of difference in non–lung-cancer mortality between cohorts, 
suggests that failure to identify subsets of patients with MLN 
metastasis is the etiology of the survival difference. Because 
patients with larger tumors21,22 and those with N1 nodal metas-
tases23,24 are more likely to have MLN metastasis, failure to 
examine MLN in these patients is more likely to be associated 
with missed MLN disease, hence higher risk of understaging, 
with negative consequences for postoperative decision mak-
ing and long-term survival.
Almost two thirds of patients had no MLNs exam-
ined, similar to other reports. Little et al.25 found that 42% of 
TABLE 2.  Adjusted Association between Mediastinal Lymph Nodes Examined and Mortality in Sequentially Adjusted Model 
Models 
All-Cause Mortality
HR (95%CI) p
Lung Cancer Specific Mortality
HR (95%CI) p
Overall
Model 1: demographic characteristics 0.89 (0.85–0.93) <0.001 0.87 (0.82–0.92) <0.001
Model 2: demographic + clinical characteristics 0.88 (0.84–0.92) <0.001 0.85 (0.80–0.90) <0.001
Model 3: model 2 + number of LNs examined 0.93 (0.88–0.97) <0.001 0.89 (0.84–0.95) <0.001
Model 4: model 3 + number of LN metastasis detected 0.93 (0.89–0.98) 0.008 0.91 (0.86–0.97) 0.003
Among those without detected LN metastasis (pN0), n = 9652
Model 1: demographic characteristics 0.93 (0.88–0.98) 0.006 0.92 (0.86–0.99) 0.019
Model 2: demographic + clinical characteristics 0.90 (0.86–0.95) <0.001 0.89 (0.83–0.95) 0.001
Model 3: model 2 + number of LNs examined 0.95 (0.90–1.01) 0.086 0.93 (0.87–1.01) 0.072
Among those with detected LN metastasis (pN1), n = 2697
Model 1: demographic characteristics 0.82 (0.75–0.90) <0.001 0.79 (0.71–0.87) <0.001
Model 2: demographic + clinical characteristics 0.81 (0.74–0.88) <0.001 0.79 (0.71–0.87) <0.001
Model 3: model 2 + number of LNs examined 0.86 (0.78–0.95) <0.001 0.83 (0.75–0.93) 0.001
Model 4: model 3 + number of LN metastasis detected 0.88 (0.80–0.97) 0.013 0.86 (0.77–0.96) 0.006
LN, Lymph node; pN0, pathologic N0; pN1, pathologic N1.
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resections in a 2001 National Cancer Database cohort had no 
MLN, Varlotto et al.26 found that 49% of patients with stage I 
NSCLC in the SEER database from 1992 to 2002 had either 
no LN dissection or dissection of only N1 LNs. We found that 
42% of a Memphis cohort had no MLN.27 Including patients 
with pN2 and N3 disease, 48% of patients in the current anal-
ysis had no MLN. We excluded patients without examination 
of any LN (pNX), who constitute approximately 17% of the 
TABLE 3.  Multivariate Adjusted Association Between Mediastinal Lymph Node Examination Status and Mortality 
 Variables
All-Cause Mortality Lung Cancer Specific Mortality
HR (95%CI) p HR (95%CI) p
Mediastinal LN examined (reference: no examination)
Yes 0.93 (0.88–0.97) 0.002 0.89 (0.84–0.95) <0.001
Age, years 1.03 (1.03–1.04) <0.001 1.01 (1.00–1.02) <0.001
Race (reference: white)
Black 1.18 (1.09–1.28) <0.001 1.16 (1.05–1.27) 0.004
Other 0.90 (0.82–0.99) 0.025 0.92 (0.82–1.03) 0.140
Sex (reference: male)
Female 0.72 (0.69–0.76) <0.001 0.85 (0.81-0.91) <0.001
Marital status (reference: married)
living alone 1.19 (1.14–1.25) <0.001 1.05 (0.99–1.11) 0.099
Tumor location (reference: upper lobe)
Middle lobe 1.18 (1.06–1.31) 0.002 1.23 (1.08–1.40) 0.002
Lower lobe 1.10 (1.05–1.16) <0.001 1.17 (1.11–1.25) <0.001
Multiple lobe or unspecified 1.14 (1.03–1.26) 0.009 1.21 (1.07–1.37) 0.002
AJCC Stage, 3rd version (reference: stage I)
II 1.68 (1.58–1.78) <0.001 1.96 (1.83–2.11) <0.001
III 1.94 (1.76–2.15) <0.001 2.23 (1.96–2.53) <0.001
Histology (reference: adenocarcinoma)
Squamous cell carcinoma 1.01 (0.96–1.06) 0.748 0.85 (0.80–0.91) <0.001
Large cell carcinoma 0.99 (0.88–1.12) 0.902 0.92 (0.79–1.07) 0.279
Bronchioalveolar cell carcinoma 0.82 (0.76–0.90) <0.001 0.88 (0.79–0.97) 0.007
Other 0.99 (0.92–1.07) 0.865 0.93 (0.84–1.02) 0.224
Tumor grade (reference: well differentiation)
Moderate 1.35 (1.23–1.48) <0.001 1.32 (1.18–1.47) <0.001
Poor 1.45 (1.32–1.58) <0.001 1.43 (1.28–1.60) <0.001
Undifferentiated 1.56 (1.35–1.81) <0.001 1.53 (1.27–1.85) <0.001
Other 1.34 (1.20–1.50) <0.001 1.33 (1.16–1.53) <0.001
Tumor size (cm) (reference: <3cm)
3–4.9 1.22 (1.16–1.29) <0.001 1.26 (1.18–1.35) <0.001
≥5 1.45 (1.36–1.54) <0.001 1.63 (1.51–1.76) <0.001
Unknown 1.34 (1.20–1.50) <0.001 1.33 (1.10–1.64) 0.004
Tumor extension (reference: confined to one lung)
Involving main stem bronchus 1.10 (1.04–1.15) <0.001 1.17 (1.10–1.24) 0.053
Extended to pleura, visceral or NOS 0.91 (0.81–1.02) <0.001 0.87 (0.75–1.01) 0.065
Postsurgery radiation (reference: no radiation)
Yes 1.27 (1.20–1.35) <0.001 1.34 (1.24–1.44) <0.001
Extent of resection (reference: lobectomy)
Pneumonectomy 1.16 (1.08–1.25) <0.001 1.14 (1.05–1.25) 0.003
Other 1.27 (1.17–1.38) <0.001 1.24 (1.12–1.38) <0.001
No. of LNs examined (reference: 1–3)
4–5 0.95 (0.88–1.01) 0.108 0.92 (0.85–1.01) 0.073
6–8 0.85 (0.80–0.91) <0.001 0.84 (0.77–0.91) <0.001
9–12 0.87 (0.81–0.94) <0.001 0.87 (0.79–0.95) 0.002
 ≥13 0.75 (0.70–0.81) <0.001 0.76 (0.69–0.84) <0.001
LN, lymph node; AJCC, American Joint Committee on Cancer; HR, hazard ratio; CI, confidence interval; NOS, not otherwise specified.
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SEER database26 because some may have been marginally fit 
for surgery as evidenced by their relatively high wedge resec-
tion rate, and so an unknown proportion may have competing 
reasons for a higher mortality rate.28 However, if fit patients 
who undergo a pNX resection are considered, the problem 
may be worse than we report.
Our study is limited by the limitations of the SEER 
database, such as its retrospective design, the absence of cer-
tain clinical information such as patients’ performance status, 
preoperative staging details, the status of surgical resection 
margins, and the use of chemotherapy. For example, we were 
constrained to restrict analysis to the 1998–2002 resection 
population because of the absence of information from other 
eras. It is possible that current surgical practice has improved 
since 2002. However, this seems unlikely, given the results of 
our analysis of surgical practice in a U.S. metropolitan area 
from 2004 to 2007.29,30
Our retrospective study design precludes determina-
tion of the etiology of failure to examine MLN. We can only 
speculate. A high rate of failure to examine MLN may be a 
sign of poor overall program quality which leads, via multiple 
avenues (not only stage misattribution) to poor outcomes. We 
speculate that multiple factors contribute to the quality gap 
we demonstrated in this report, for example, surgeon factors 
(specialty training,31–33 case-volume),34 institutional factors 
(case-volumes,35,36 teaching status),37 and heterogeneity in 
pathology practice.38,39 Solutions to the problem will require 
elucidation of the relative impact of processes in each of these 
areas. Irrespective of etiology, the effect of failing to exam-
ine MLNs is large, the problem is highly prevalent,25–27,30 and 
the impact of corrective action is potentially huge, as we have 
demonstrated in our pilot studies of corrective interventions 
within the operating room40 and in the pathology laboratory.39
Other limitations arise from our combination of all types 
of MLN examination, despite the likely survival differences 
between those with varying degrees of thoroughness of exam-
ination.41 For example, patients who undergo random MLN 
sampling have a worse survival than those who undergo sys-
tematic nodal dissection.19,42 We were constrained to compare 
the binary cohorts of patients with and without MLN exami-
nation, irrespective of the number or location of the stations 
because SEER does not report the number of N1, N2, and N3 
LNs examined (or positive), nor does it identify the type of 
MLN collection procedure performed. Even if it did, the infor-
mation is unlikely to be accurate, as we have demonstrated 
in a close review of surgeons’ operation notes and pathology 
reports from all lung resection cases performed from 2004 
to 2007 in a metropolitan U.S. area.30,43 Therefore, it seems 
likely that our report significantly underestimates the nega-
tive survival impact of failing to properly examine the MLNs, 
because the MLN examination group in our study probably 
included a large number of cases in which systematic nodal 
dissection was not performed.
Finally, we are unable to analyze the impact of chemo-
therapy on the survival differences in this data set. Differences 
in the use of pre- or postoperative chemotherapy may account 
for the differences we report. This is unlikely because the use 
of adjuvant chemotherapy was uncommon in the 1998–2002 
time span covered by our analysis. However, it is possible 
that routine use of postoperative adjuvant chemotherapy in 
patients with stage II and III NSCLC can reduce the survival 
difference that we report because the survival benefit of post-
operative adjuvant chemotherapy is approximately 5% (HR 
for death, 0.89),7 which is similar to the survival deficit in 
those without MLN examination (Table 2). However, most 
patients with pN0 and undetected MLN skip metastasis would 
have been deprived the benefit of postoperative adjuvant che-
motherapy and the magnitude of the survival difference in the 
pN1 patients exceeds the expected benefit of current postop-
erative adjuvant chemotherapy.
In conclusion, nonexamination of MLNs is associated 
with impaired survival in a large population in the United 
States. This is especially important now that improving upon 
the results of recent adjuvant therapy trials is the objective of 
intense ongoing research activity. Studies to localize the etiol-
ogy of this quality gap in surgical oncology practice are much 
needed. Logically conceived, and carefully implemented, 
interventions to eliminate the gap must be promoted.
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